COVID–19 and Pandemic Response Centers of Excellence Act of 2021

COVID-19 response General hospital policies H.R. 4292 - COVID-19 and Pandemic Response Centers of Excellence Act; S. 2307 - COVID-19 and Pandemic Response Centers of Excellence Act of 2021. S. 3799 - PREVENT Pandemics Act. National Cancer Center Federal Designation. Inflation Reduction Act (H.R. 5376) Public Law No. 117-169. H.R. 6833 - Continuing Resolution.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5699 & S. 2114, The Student Assisted Vaccination Effort (SAVE) Act: all provisions. General issues related to pandemic response: all provisions. H.R. 4292/S.2307, the COVID-19 and Pandemic Response Centers of Excellence Act: all provisions. S.340/H.R.4791 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; all provisions.

Client expense: $93,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Met with legislative staff to express support for biomedical research. Urged legislative staff to cosponsor the RISE Act (HR 869, S 289) to authorize supplemental funding to NIH to cover extraordinary COVID-19-related costs to biomedical research. Urged legislative staff to support a proposal to create and fund a COVID-19 and Pandemic Response Centers of Excellence program (HR 4292, S 2307). Urged legislative staff to support S 168/HR 708, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act. Urged legislative staff to address telehealth provisions CMS identified as under Congress purview including audio-only visits and the ability for telehealth services to be provided to both new and established patients for acute and chronic conditions. Urged agency staff to create a dedicated fund within the provider relief fund to provide relief to faculty practice plans. Asked Representatives to consider legislation that makes changes to the regulation of laboratory testing (including the VALID Act) separately from the Medical Device User Fee Agreement (MDUFA) V legislative process.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

COVID-19 response General hospital policies H.R. 4292 - COVID-19 and Pandemic Response Centers of Excellence Act; S. 2307 - COVID-19 and Pandemic Response Centers of Excellence Act of 2021. H.R. 5376 - Build Back Better Act. S. 3799 - PREVENT Pandemics Act. National Cancer Center Federal Designation.

Client expense: Not reported · Firm income: $50,000

H.R. 2256, Resident Physician Shortage Reduction Act of 2021 H.R. 2471, Consolidated Appropriations Act, 2022; Medicaid shortfall definition; telehealth issues; CMS Acute Hospital Care at Home issues; pandemic provider relief; Medicare sequestration relief H.R. 5585, Advanced Research Project Agency-Health Act (ARPA-H) H.R. 6000, 21st Century Cures 2.0 Act; Cancer Moonshot funding for the National Institutes of Health (NIH); ARPA-H related issues S. 2307, COVID-19 and Pandemic Response Centers of Excellence Act of 2021 S. 3799, Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act; infrastructure support issues; Pandemic Response Centers of Excellence; surveillance testing issues Declaration of Public Health Emergency related issues National Institute of Health (NIH) Facilities and Administrative Costs related issues S. 2209, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; issues related to Medical Device User Fee Authorization legislation Distribution of Health and Human Services (HHS) COVID-19 treatments related issues

Client expense: $520,000 · Firm income: Not reported

Met with legislative staff to express support for full funding of the National Institutes of Health, the Agency for Healthcare Research & Quality (AHRQ), and the Title VII Health Professions Programs, in the FY 22 budget and appropriations process. (PL 117-103, Division H) Met with legislative staff to express support for biomedical research. Urged legislative staff to cosponsor the RISE Act (HR 869, S 289) to authorize supplemental funding to NIH to cover extraordinary COVID-19-related costs to biomedical research. Urged legislative staff to support a proposal to create and fund a COVID-19 and Pandemic Response Centers of Excellence program (HR 4292, S 2307). Urged legislative staff to support S 168/HR 708, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act. Urged legislative staff to address telehealth provisions CMS identified as under Congress purview including audio-only visits and the ability for telehealth services to be provided to both new and established patients for acute and chronic conditions. Urged agency staff to create a dedicated fund within the provider relief fund to provide relief to faculty practice plans. Asked Representatives to consider legislation that makes changes to the regulation of laboratory testing (including the VALID Act) separately from the Medical Device User Fee Agreement (MDUFA) V legislative process.

Client expense: $140,000 · Firm income: Not reported

H.R. 5699 & S. 2114, The Student Assisted Vaccination Effort (SAVE) Act: all provisions General issues related to pandemic response: all provisions H.R. 4292/S.2307, the COVID-19 and Pandemic Response Centers of Excellence Act: all provisions S.340/H.R.4791 "Telehealth Response for E-prescribing Addiction Therapy Services Act": all provisions

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

COVID-19 response General hospital policies H.R. 4292 - COVID-19 and Pandemic Response Centers of Excellence Act; S. 2307 - COVID-19 and Pandemic Response Centers of Excellence Act of 2021. H.R. 5376 - Build Back Better Act. H.R. 2471 - Consolidated Appropriations Act (2022 Omnibus). S. 3799 - PREVENT Pandemics Act. H.R. 7007 - COVID-19 Supplemental Appropriations Act of 2022.

Client expense: Not reported · Firm income: $50,000

General issues related to pandemic response H.R. 4292/S.2307, the COVID-19 and Pandemic Response Centers of Excellence Act All provisions

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Met with legislative staff to express support for full funding of the National Institutes of Health, the Agency for Healthcare Research & Quality (AHRQ), and the Title VII Health Professions Programs, in the FY 22 budget and appropriations process. (HR 4502) Met with legislative staff to express support for biomedical research. Urged legislative staff to cosponsor the RISE Act (HR 869, S 289) to authorize supplemental funding to NIH to cover extraordinary COVID-19-related costs to biomedical research. Urged legislative staff to include funding and express language to provide relief for providers in hot spot areas directly addressing the COVID-19 pandemic. Urged legislative staff to support a proposal to create and fund a COVID-19 and Pandemic Response Centers of Excellence program (HR 4292, S 2307). Urged legislative staff to support S 168/HR 708, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act. Urged legislative staff to address telehealth provisions CMS identified as under Congress purview including audio-only visits and the ability for telehealth services to be provided to both new and established patients for acute and chronic conditions. Urged agency staff to create a dedicated fund within the provider relief fund to provide relief to faculty practice plans.

Client expense: $90,000 · Firm income: Not reported

COVID-19 response General hospital policies H.R. 4292 - COVID-19 and Pandemic Response Centers of Excellence Act; S. 2307 - COVID-19 and Pandemic Response Centers of Excellence Act of 2021. H.R. 5376 - Build Back Better Act.

Client expense: Not reported · Firm income: $50,000

H.R. 5376, the Build Back Better Act. H.R. 3733, Essential Caregivers Act. H.R. 3321/S. 1670 - Credit for Caring Act No bill number. Discussed visitation protocols, mental health needs, dementia, and short-term delirium in hospitals. S. 2890, Provider Training in Palliative Care Act. No bill number. Discussed advanced illness/end-of-life. No bill number. Discussed Covid-19, nursing home and long-term care facility residents and staff, visitation, vaccination, boosters. No bill number. Discussed crisis standards of care. No bill number. Discussed long-term services and supports workforce roundtable. No bill number. Comment letter to the Centers for Medicare & Medicaid Services on the interim final rule with comment on COVID-19 health care worker vaccination requirements for certain Medicare and/or Medicaid certified providers and suppliers. P.L. 117-2. American Rescue Plan Act. H.R. 4502, Labor, Health & Human Services Appropriations Act, FY 2022. S.2307, the COVID-19 and Pandemic Response Centers of Excellence Act of 2021. No bill number. Discussed the Supplemental Nutrition Assistance Program. H.R. 5724/S. 3064, White House Conference on Food, Nutrition, Hunger, and Health Act. S. 19, FEED Act. S. 2210/H.R. 4131, Better Care Better Jobs Act. S. 3431, the Revitalizing the Aging Network Act. No bill number. Aging Innovation Act. No bill number. Discussed United States Preventive Services Task Force report to Congress. Discussed draft insulin legislation.

Client expense: $5,140,000 · Firm income: Not reported

S. 2307 and H.R. 4292, COVID-19 and Pandemic Centers of Excellence ActAll Provisions

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Met with legislative staff to express support for full funding of the National Institutes of Health, the Agency for Healthcare Research & Quality (AHRQ), and the Title VII Health Professions Programs, in the FY 22 budget and appropriations process. (HR 4502) Met with legislative staff to express support for biomedical research. Urged legislative staff to cosponsor the RISE Act (HR 869, S 289) to authorize supplemental funding to NIH to cover extraordinary COVID-19-related costs to biomedical research. Urged legislative staff to include funding and express language to provide relief for providers in hot spot areas directly addressing the COVID-19 pandemic. Urged legislative staff to support a proposal to create and fund a COVID-19 and Pandemic Response Centers of Excellence program (HR 4292, S 2307). Urged legislative staff to support S 168/HR 708, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act. Urged legislative staff to address telehealth provisions CMS identified as under Congress purview including audio-only visits and the ability for telehealth services to be provided to both new and established patients for acute and chronic conditions. Urged agency staff to create a dedicated fund within the provider relief fund to provide relief to faculty practice plans.

Client expense: $120,000 · Firm income: Not reported

S. 2307 and H.R. 4292, COVID-19 and Pandemic Centers of Excellence ActAll Provisions

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

COVID-19 response General hospital policies H.R. 4292 - COVID-19 and Pandemic Response Centers of Excellence Act; S. 2307 - COVID-19 and Pandemic Response Centers of Excellence Act of 2021. The Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022 S. Con. Res. 14.

Client expense: Not reported · Firm income: $50,000

S. 2307 and H.R. 4292 - COVID-19 and Pandemic Centers of Excellence Act; Calls with staff of Rep. Beatty, and Balderson, and Sens. Brown, Portman, and Gillibrand; also pandemic centers of excellence appropriations request H.R. 1319, American Rescue Plan Act implementation H.R. 1868, Medicare sequestration fix H.R. 708/ S 168, Temporary Reciprocity to Ensure Access to Treatment Act (TREAT Act) S 834, Resident Physician Shortage Reduction Act Maintain the 340B drug pricing program (no current bill) Support H.R. 1550, Prevent HPV Cancer Act of 2021 (with the ADCC) Comments submitted on the FY 2022 Medicare Inpatient Prospective Payment System Proposed Rule development of H.R. 4347, Balderson remote patient monitoring legislation General IssuesMaintaing the 340B drug pricing program; all provisions General Issues Medicare Hospital Outpatient Prospective Payment System (OPPS) CY 2019; provisions related to cuts to hospital outpatient departments S.4791 "Telehealth Response for E-prescribing Addiction Therapy Services Act (S.340)" H.R. 8474 All Provisions

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE

Met with legislative staff to express support for full funding of the National Institutes of Health, the Agency for Healthcare Research & Quality (AHRQ), and the Title VII Health Professions Programs, in the FY 22 budget and appropriations process. (No bill number) Met with legislative staff to express support for biomedical research. Urged legislative staff to cosponsor the RISE Act (HR 869, S 289) to authorize supplemental funding to NIH to cover extraordinary COVID-19-related costs to biomedical research. Urged legislative staff to include funding and express language to provide relief for providers in hot spot areas directly addressing the COVID-19 pandemic. Urged legislative staff to support a proposal to create and fund a COVID-19 and Pandemic Response Centers of Excellence program (HR 4292, S 2307). Urged legislative staff to support S 168/HR 708, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act. Urged legislative staff to address telehealth provisions CMS identified as under Congress purview including audio-only visits and the ability for telehealth services to be provided to both new and established patients for acute and chronic conditions. Urged agency staff to create a dedicated fund within the provider relief fund to provide relief to faculty practice plans.  

Client expense: $130,000 · Firm income: Not reported